Petrygium often causes dry eyes which result in much discomfort and frustration. We are documenting a dry eye treatment for Petrygium that avoids the use of surgery.
What is Petrygium
Pterygium is a growth of thin tissue on the conjunctiva that covers your eyeball. This growth can be slow and extends to cover part of the cornea. This condition is called Pterygium, also referred to as “Surfer’s Eye” because it is caused by extensive exposure to sunlight. In addition, pterygium is often started as a Pinguecula.
What is Pinguecula
Pinguecula is a yellow spot or bump on the corner of your eye that looks like a yellow fat deposit. A pinguecula often gets bigger and develops into a pterygium. When this happens, the friction between your eyelid and the pterygium tissue causes inflammation and result in dry eyes. Dry eye symptoms such as itchy, foreign body sensation and red eyes are common. Therefore, this causes much pain and suffering.
How Do Eye Doctors Treat Pterygium?
Eye doctors often recommend eye drops, and steroid drops for symptom relief. Depending on how severe the dry eye symptoms are, however, eye drops may not work. In addition, steroid drops1 are known to cause side effects such as increased intraocular pressure resulting in Glaucoma, or damages to the liver and kidney.
When the Pterygium growth becomes extensive and large, eye doctors often recommend surgery. However, eye surgeries tend to result in dry eyes afterward due to the invasive nature of the procedure. What is more, other complications after Pterygium surgery has been documented2. Therefore, avoid surgery would be highly desirable if there are other non-invasive alternatives. TheraLife presents a dry eye treatment opportunity for Pterygium without the use of surgery.
What Are Chronic Dry Eyes?
Chronic dry eyes happens when one do not produce enough tears (tear insufficiency), or tear is too thin resulting in evaporative dry eye. The causes for dry eyes include but not limited to computer over use, contact lens wear, menopause, aging, and autoimmune diseases. The symptoms of chronic dry eyes include blurry vision, foreign body sensation, light sensitivity, red irritated eyes, puffy eye lids, and eye pain. Besides, chronic dry eyes also lead to complications of Blepharitis, Meibomian Gland Dysfunction (MGD), cornea abrasions and more. What is more, chronic dry eyes left untreated could lead to blindness. All these symptoms can be involved in people with Pterygium.
How Does TheraLife Treat Dry Eyes Cause by Pterygium?
TheraLife Eye capsules is an effective dry eye treatment for chronic dry eyes, including the symptoms caused by pterygium. TheraLife Eye capsules increases tear production, reduce inflammation, and ease eye pain caused by surfer’s eye. It restores tear productions from inside out. Better yet, it is 100% natural, suitable for vegans.
A personal story from one of TheraLife’s customers
“I developed pterygium(surfer’s eye) in both eyes in 2006 due to dry eyes. I also started menopause – the hormoneimbalance makes dry eye symptoms worse. My Tear Breakup Test was only 1 sec. Normal is between 10-15. I alsohad MGD (meibomian gland dysfunction) where my oil glands are clogged. I started taking Theralife Eye capsules,krill and fish oil; hot compresses daily, and a healthy smoothie to fortifynutrients for the eyes. I used a gel compress over my eyes to keep my eyelidsclosed. I had a high-stress job for years which makes dry eye symptoms worse.My cholesterol level is now normal- hopefully, this will prevent furtherclogging of the Meibomian oil glands. There are many factors to affect dry eyes. However, since I started theTheraLife protocol, it is making a difference. I am making more of my own natural tears, and pterygium stopped being aproblem.
I am grateful to have found TheraLife.”
A. Lurenci- California, USA
1.Long Term and Intensive Use of Ophthalmic TopicalCorticosteroids and the Risk of Positive Doping Test in Athletes: A Case Report https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4594141/
2.Seriouscorneoscleral complications after pterygium excision with mitomycin C– Br J Ophthalmol. 2002 Mar; 86(3): 357–358.